Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRUCIAL phase II in inoperable esophageal cancer
2018-000053-53Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) and esophageal adenocarcinoma (EAC) comparing Definitive chemoradiotherapy + nivolumab with Definitive chemoradiotherapy + nivolumab + ipilimumab (2 arms). Primary endpoints: Progression-free survival rate at 12 months, Feasibility and 1 more. Started Jul 2018; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2018-000053-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000053-53.